Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved

AETHLON MEDICAL INC

Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.
Cash balance of $5.4M at March 31, 2024, increased to $9.1M as of June 25, 2024.
Received HREC ethics approval for Hemopurifier safety/feasibility oncology trial in Australia, valid through 2027.
FDA approved internal manufacturing facility in April 2024.
COVID-19 trial in India remains open with one patient treated; monitoring H5N1 avian flu situation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.